|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 2458 | Drugs / Medical | 09/06/2003
Kahn Gauthier Swick is investigating possible legal actions against EndoVascular Technologies, Inc., a wholly-owned subsidiary of medical device manufacturer Guidant Corporation, on behalf of persons who were implanted with EndoVascular's Ancure Endograft System, which is used to repair abdominal aorta aneurysms. EndoVascular has now admitted that it lied to the government and concealed serious problems with the device, leading to at least a dozen deaths. The company has also pled guilty to 10 felonies in a prosecution by the U.S. government.
The federal Food and Drug Administration approved the Ancure system on September 28, 1999. The scope of the problems began to surface in the fall of 2000, when seven anonymous employees sent a letter to the FDA providing details about the failures and problems that were occurring. EndoVascular recalled the Ancure system on March 16, 2001, and reintroduced it in August of that year. While the company previously submitted 172 reports of problems, it has now admitted that the real number was much higher: 2,628 additional reports of problems, out of a total of 7,632 devices that were sold. The problems with the device centered on the system used to insert it. The equipment could become lodged, potentially requiring emergency surgery to remove it. In some cases, it was broken into pieces before being removed--a technique devised by sales representatives. Aortic Aneurysm Can Be A KillerApproximately 40,000 patients undergo repair of abdominal aortic aneurysm in the United States each year. In spite of that, approximately 15,000 patients die from ruptured aneurysm, making aneurysm rupture the 13th leading cause of death in the United States. This cause of premature death is entirely preventable providing that patients with abdominal aortic aneurysm can be diagnosed prior to rupture and undergo safe elective repair of the abdominal aortic aneurysm. Historically, doctors dealt with abdominal aneurysms through complex surgery. That entailed opening the abdominal cavity, moving aside the patient's internal organs, finding the aorta and locating the aneurysm--a spot where the vessel is weakened and balloons out. Once that is found, the surgeon would attach a graft to strengthen that point in the aorta. The newer method advanced by EndoVascular avoided the dangers and complications of surgery. With it, a doctor inserted a catheter containing a polyester graft into an artery in the groin, then threaded it through the body until it reached the aneurysm. EndoVascular/Guidant has said that, because the initial risk from the device came from the equipment used to insert it, patients who have the device are not in danger. A competing product, the AneuRx stent graft system, is made by Medtronic AVE. Register your Endovascular Technologies Ancure Endograft System ComplaintIf you or someone you know has been affected by this case, you may qualify for a money settlement as the result of your financial/economic or other damages that may be awarded either prior to a lawsuit or after the initiation of a lawsuit either currently in progress or filed just for you, possibly a class action lawsuit. Please simply register your complaint by clicking here for Endovascular Technologies Ancure Endograft System, or click the red "submit" button on this page, and a lawyer will review your Endovascular Technologies Ancure Endograft System complaint. By submitting your complaint, you are asking lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered - the lawyers work on "contingency" by fronting the costs of your lawsuit based on their belief that they will recover a settlement for you. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest Several class actions have been filed against medical products and services company Cardinal Health, Inc., (NYSE:CAH) and certain of its officers and directors by stockholders who purchased the company's common stock between October 24, 2000, and June 30, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The issue of corporate health plan prescription contraceptive coverage is a hot-button item lately. The parties have apparently reached a settlement in a nationwide action filed against supermarket chain Albertson's, Inc. on behalf of female employees who allege that the store and its subsidiaries have discriminated against them by refusing to pay for their prescription contraceptives, in violation of their civil rights.
Studies have now shown that light cigarette smokers compensate in various ways to make up for reduced levels of nicotine that they get. Two classes have been certified in Missouri class actions filed against cigarette makers R.J. Reynolds Tobacco Company and the Philip Morris Companies, now known as the Altria Group, on behalf of light cigarette smokers, who allege that the companies violated state consumer fraud laws in the marketing of light and low-tar cigarettes. Several class actions have been filed against biopharmaceutical research company Allos Therapeutics, Inc., (Nasdaq:ALTH) and certain of its officers and directors by stockholders who purchased the company's common stock between April 23, 2003, and April 29, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. A class action has been filed against Maxim Pharmaceuticals, Inc., a global biopharmaceuticals company (NASDAQ:MAXM) and certain of its officers and directors by stockholders who purchased the company’s common stock between November 11, 2002 and September 17, 2004. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company’s securities. The stockholder seek to recover compensatory damages for the loss of value of their stock. In this day of incurable transmissible diseases, it would be nice to be confident that the needle that gets stuck in your arm has never been used before. On November 5, 2003, the court granted preliminary approval to the parties' $25 million proposed settlement in a class action filed against Oklahoma's Norman Regional Hospital, a clinic administrator, and nurse anesthetist James Hill who is accused of reusing needles when administering intravenous pain medicine to patients in the hospital's clinic in violation of state medical regulations. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
